

Sabrina Hoa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6925133/sabrina-hoa-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

154
citations

7
h-index

12
g-index

21
ext. papers

284
ext. citations

6.2
avg, IF

2.61
L-index

#	Paper	IF	Citations
17	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. <i>European Respiratory Review</i> , 2018 , 27,	9.8	32
16	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 5	5.7	29
15	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020 , 19, 102595	13.6	22
14	Towards developing criteria for scleroderma renal crisis: A scoping review. <i>Autoimmunity Reviews</i> , 2017 , 16, 407-415	13.6	21
13	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
12	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. <i>RMD Open</i> , 2020 , 6,	5.9	9
11	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2197-2207	7.4	7
10	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. <i>Autoimmunity Reviews</i> , 2021 , 20, 102851	13.6	3
9	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1108-1117	3.9	3
8	Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 103-129	2.3	3
7	Mortality and morbidity in scleroderma renal crisis: A systematic literature review.. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 21-36	2.3	3
6	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021 , 160, 2158-2162	5.3	1
5	Risk of rheumatic disease in breast implant users: a qualitative systematic review. <i>Gland Surgery</i> , 2021 , 10, 2557-2576	2.2	0
4	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 142-148	2.2	0
3	Cutaneous Lymphangiectasia in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 446	9.5	
2	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. <i>Respiratory Medicine</i> , 2021 , 185, 106482	4.6	
1	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 142-148	2.2	

